The effect of the parenteral Route of administration on the immune response to simultaneous nasal and parenteral immunizations using a New HBV therapeutic vaccine candidate

Viral Immunology

Volumn 23, Issue 5, 2010, Pages 521-529

  Lobaina, Yadira ^a   Trujillo, Heidy ^a   García, Daymir ^a   Gambe, Aylin ^a   Chacon, Yahima ^a   Blanco, Aracelys ^a   Aguilar, Julio Cesar ^a  

^a CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Cuba)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM POTASSIUM SULFATE; GAMMA INTERFERON; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; MEMBRANE ANTIGEN;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIGENICITY; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; IMMUNOGENICITY; INTRANASAL DRUG ADMINISTRATION; NONHUMAN; PARENTERAL DRUG ADMINISTRATION; SUBCUTANEOUS DRUG ADMINISTRATION; TRANSGENIC MOUSE; VACCINATION; VIRUS NUCLEOCAPSID;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ALUM COMPOUNDS; ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS B VACCINES; HEPATITIS B VIRUS; INJECTIONS, INTRADERMAL; INJECTIONS, INTRAMUSCULAR; INJECTIONS, SUBCUTANEOUS; INTERFERON-GAMMA; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; T-LYMPHOCYTES; VACCINATION;

HEPATITIS B VIRUS; MUS; MUS MUSCULUS;

EID: 77957734372     PISSN: 08828245     EISSN: None     Source Type: Journal    
DOI: 10.1089/vim.2010.0024     Document Type: Article

References (42)

1. Aguilar JC, Lobaina Y, Muzio V, et al.: Development of a nasal vaccine for chronic hepatitis B infection that uses the ability of hepatitis B core antigen to stimulate a strong Th1 response against hepatitis B surface antigen. Immunol Cell Biol 2004;82:539-546.
2. Aguilar A, González CA, Cinza Z, et al.: Phase I clinical trial in healthy adults of a nasal vaccine candidate containing recombinant hepatitis B surface and core antigens. Int J Infect Dis 2007;11:394-401.
3. Beckebaum S, Cicinnati VR, Zhang X, et al.: Hepatitis B virus-induced defect of monocyte-derived dendritic cells leads to impaired T helper type 1 response in vitro: mechanisms for viral immune escape. Immunology 2003;109:487-495.
4. Bertoletti A, and Naoumov NV: Translation of immunological knowledge into better treatments of chronic hepatitis B. J Hepatol 2003;39:115-124.
5. Bertoletti A, Ferrari C, and Fiaccadori F: Role of the cellmediated immune response in the pathogenesis of hepatitis B virus infection: possible immune-therapeutic strategies. Acta Biomed Ateneo Parmense 1996;67:87-93.
6. Bertoletti A, and Gehring AJ: The immune response during hepatitis B virus infection. J Gen Virol 2006;87:1439-1449.
7. Boni C, Penna A, Ogg GS, et al.: Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy. Hepatology 2001;33:963-971.
8. Castro FO, Pérez A, Aguilar DG, Martínez R, Dela Fuente J, and Herra L: Expresión del gen del antigeno de superficie del virus de la hepatitis B en ratones transgénicos. Interferón y Biotecnología 1989;6:251-257.
9. Eo SK, Gierynska M, Kamar AA, and Rouse BT: Prime-boost immunization with DNA vaccine: mucosal route of administration changes the rules. J Immunol 2001;166:5473-5479.
10. García E, González VE, González-Griego A, Salgado A, Fernández A, Pezzella M, and Alerm A: Correlación del ADN y del antigeno de superficie del virus de hepatitis B en tejidos de animales transgénicos. Rev Cubana Invest Biomed 2000;19:8-9.
11. Goto N, Kato H, Maeyama J-I, Eto K, and Yoshihara S: Studies on the toxicities of aluminium hydroxide and calcium phosphate as immunological adjuvants for vaccines. Vaccine 1993;11:914-918.
12. Hilleman MR: Overview of the pathogenesis, prophylaxis and therapeusis of viral hepatitis B, with focus on reduction to practical applications. Vaccine 2001;19:1837-1848.
13. Hoofnagle JH, Doo E, Liang TJ, Fleischer R, and Lok A S F: Management of hepatitis B: summary of a clinical research workshop. Hepatology 2007;45:1056-1075.
14. Horiike N, Akbar F, Michitaka K, et al.: In vivo immunization by vaccine therapy following virus suppression by lamivudine: a novel approach for treating patients with chronic hepatitis B. J Clin Virol 2005;32:156-161.
15. Iglesias E, Franch O, Carrazana Y, et al.: Influence of aluminum-based adjuvant on the immune response to multiantigenic formulation. Viral Immunol 2006;19:4.
16. Iglesias E, García D, Carrazana Y, Aguilar JC, Sánchez A, Gorobaya L, and Blanco A: Anti-HIV-1 and anti-HBV immune responses in mice after parenteral and nasal co-administration of a multiantigenic formulation. Curr HIV Res 2008;6:452-460.
17. Iglesias E, Thompson R, Carrazana Y, Lobaina Y, Garcia D, et al.: Coinoculation with hepatitis B surface and core antigen promotes a Th1 immune response to a multiepitopic protein of HIV-1. Immunol Cell Biol 2006;84:174-183.
18. Lau GK, Suri D, Liang R, et al.: Resolution of chronic hepatitis B and anti-HBs seroconversion in humans by adoptive transfer of immunity to hepatitis B core antigen. Gastroenterology 2002;122:614-624.
19. Li YG, Chen M, Zhang DZ, et al.: Clinical research on the treatment effect of autologous dendritic cell vaccine on the patients with chronic hepatitis B. Zhonghua Gan Zang Bing Za Zhi 2003;11:206-208.
20. Liaw YF, Leung NW, Chang TT, et al.: Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology 2000;119:172-180.
21. Lobaina Y, Palenzuela D, Pichardo D, Muzio V, Guillen G, and Aguilar JC: Immunological characterization of two hepatitis B core antigen variants and their immunoenhancing effect on co-delivered hepatitis B surface antigen. Mol Immunol 2005;42:289-294.
22. Makitalo B, Lundholm P, Hinkula J, et al.: Enhanced cellular immunity and systemic control of SHIV infection by combined parenteral and mucosal administration of a DNA prime MVA boost vaccine regimen. J Gen Virol 2004;85:2407-2419.
23. Mandell GL, Bennet JE, and Dolin R: Principles and Practice of Infectious Diseases, 5th ed (CD-ROM). Churchill Livingstone, New York, 2000.
24. Mestecky J, Michalek SM, Moldoveanu Z, and Russell MW: Routes of immunization and antigen delivery systems for optimal mucosal immune responses in humans. Behring Inst Mitt 1997;98:33-43.
25. Neutra RM, Pringault E, and Kraehenbuhl J-P: Antigen sampling across epithelial barriers and induction of mucosal immune responses. Ann Rev Immunol 1996;14:275.
26. Peters M, Vierling J, Gershwin ME, Milich D, Chisari FV, and Hoofnagle JH: Immunology and the liver. Hepatology 1991;13:977-994.
27. Petrovsky N, and Aguilar JC: Vaccine adjuvants: Current state and future trends. Immunol Cell Biol 2004;82:488-496.
28. Riedl P, Buschle M, Reimann J, and Schirmbeck R: Binding immune-stimulating oligonucleotides to cationic peptides from viral core antigen enhances their potency as adjuvants. Eur J Immunol 2002;32:1709-1716.
29. Riedl P, Stober D, Oehninger C, Melber K, Reimann J, and Schirmbeck R: Priming Th1 immunity to viral core particles is facilitated by trace amounts of RNA bound to its argininerich domain. J Immunol 2002;168:4951-4959.
30. Schirmbeck R, Wild J, and Reimann J: Similar as well as distinct MHC class I-binding peptides are generated by exogenous and endogenous processing of hepatitis B virus surface antigen. Eur J Immunol 1998;28:4149-4161.
31. Schirmbeck R, Wild J, Stober D, Blum HE, Chisari FV, Geissler M, and Reimann J: Ongoing murine T1 or T2 immune responses to the hepatitis B surface antigen are excluded from the liver that expresses transgene-encoded hepatitis B surface antigen. J Immunol 2000;164:4235-4243.
32. Shimizu Y, Guidotti LG, Fowler P, and Chisari FV: Dendritic cell immunization breaks cytotoxic T lymphocyte tolerance in hepatitis B virus transgenic mice. J Immunol 1998;161:4520.
33. Vajdy M, Singh M, Kazzaz J, et al.: Mucosal and systemic anti-HIV responses in rhesus macaques following combinations of intranasal and parenteral immunizations. AIDS Res Hum Retroviruses 2004;20:1269-1281.
34. Vandepapeliere P, Lau G, Leroux-Roels G, et al.: Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: a randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine. Vaccine 2007;25:8585-8597.
35. Vanlandschoot P, Cao T, and Leroux-Roels G: The nucleocapsid of the hepatitis B virus: a remarkable immunogenic structure. Antiviral Res 2003;60:67-74.
36. Webster G J M, and Bertoletti A: Quantity and quality of virus specific CD8 cell response: relevance to the design of a therapeutic vaccine for chronic HBV infection. Mol Immunol 2001;38:467-473.
37. Wettendorff M: Therapeutic vaccination. Virus Res 2002;82:133-140.
38. Wieland S, Thimme R, Purcell RH, and Chisari FV: Genomic analysis of the host response to hepatitis B virus infection. Proc Natl Acad Sci USA 2004;101:6669-6674.
39. Wild J, Grusby MJ, Schirmbeck R, and Reimann J: Priming MHC-I restricted, cytotoxic T lymphocyte responses to exogenous hepatitis B surface antigen is CD41 T cell-dependent. J Immunol 1999;163:1880.
40. Wirth S, Guidotti LG, Ando K-I, Schlicht HJ, and Chisari FV: Breaking tolerance leads to autoantibody production but not autoimmune liver disease in hepatitis B virus envelope transgenic mice. J Immunol 1995;154:2504.
41. Zheng BJ, Zhou J, Qu D, et al.: Selective functional deficit in dendritic cell-T-cell interaction is a crucial mechanism in chronic hepatitis B virus infection. J Viral Hepat 2004;11:217-224.
42. Zhevachevsky NG, Nomokonova NY, Beklemishev AB, and Belov GF: Dynamic study of HBsAg and HBeAg in saliva samples from patients with hepatitis B infection: diagnostic and epidemiological significance. J Med Virol 2000;61:433-438.